Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection. Methods: The study analyzed pooled data on Korean patients with HCV infection enrolled in the ENDURANCE 1 and 2, SURVEYOR II part 4 and VOYAGE I and II trials, which evaluated the efficacy and safety of 8 or 12 weeks of G/P treatment. The patients were either treatment-naïve or had received sofosbuvir or interferon-based treatment. Efficacy was evaluated by assessing the rate of sustained virologic response at 12 weeks posttreatment (SVR12). Safety was evaluated by monitoring adverse events (AEs) and laboratory assessments. Results: The analysis included 265 patients; 179 (67.5%) were HCV treatment-naïve, and most patients were either subgenotype 1B (48.7%) or 2A (44.5%). In the intention-to-treat population, 262 patients (98.9%) achieved SVR12. Three patients did not achieve SVR12: one had virologic failure and two had non-virologic failures. Most AEs were grade 1/2; eight patients (3.0%) experienced at least one grade ≥3 AE. No serious AEs related to G/P treatment were reported, and grade ≥3 hepatic laboratory abnormalities were rare (0.8%). Conclusions: G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that observed in a pooled analysis of a global pan-genotypic population of patients with HCV infection who received G/P.
Abstract
Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection. Methods: The study analyzed pooled data on Korean patients with HCV infection enrolled in the ENDURANCE 1 and 2, SURVEYOR II part 4 and VOYAGE I and II trials, which evaluated the efficacy and safety of 8 or 12 weeks of G/P treatment. The patients were either treatment-naïve or had received sofosbuvir or interferon-based treatment. Efficacy was evaluated by assessing the rate of sustained virologic response at 12 weeks posttreatment (SVR12). Safety was evaluated by monitoring adverse events (AEs) and laboratory assessments. Results: The analysis included 265 patients; 179 (67.5%) were HCV treatment-naïve, and most patients were either subgenotype 1B (48.7%) or 2A (44.5%). In the intention-to-treat population, 262 patients (98.9%) achieved SVR12. Three patients did not achieve SVR12: one had virologic failure and two had non-virologic failures. Most AEs were grade 1/2; eight patients (3.0%) experienced at least one grade ≥3 AE. No serious AEs related to G/P treatment were reported, and grade ≥3 hepatic laboratory abnormalities were rare (0.8%). Conclusions: G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that observed in a pooled analysis of a global pan-genotypic population of patients with HCV infection who received G/P.
참고문헌 (29)
- "Global hepatitis report, 2017" (2017)[URL]
- European Association for the Study of the Liver, "European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis(EXPEDITION-1) : a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)
- Messina JP, "Global distribution and prevalence of hepatitis C virus genotypes", Hepatology, 61, pp.77~87 (2015)
- Xu F, "All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus", Clin Infect Dis, 62, pp.289~297 (2016)
- Eun Ju Cho, "Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience", Clinical and Molecular Hepatology, 18(2), pp.219~224 (2012), 대한간학회
- 정숙향, "C형 간염의 역학", 대한내과학회지, 88(6), pp.630~634 (2015), 대한내과학회[DOI]
- 정숙향, "Current status of hepatitis C virus infection and countermeasures in South Korea", Epidemiology and Health, 39, pp.1~7 (2017), 한국역학회[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Ahmet Uyanikoglu, "Durability of Sustained Virologic Response in Chronic Hepatitis C", Gut and Liver, 7(4), pp.458~461 (2013), 거트앤리버 소화기연관학회협의회
- Jong Eun Yeon, "Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD", IDSA and 2016 EASL, 2018, pp.24(3), 278~293[DOI]
- AASLD-IDSA HCV Guidance Panel, "Hepatitis C guidance 2018 update : AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection", Clin Infect Dis, 67, pp.1477~1492 (2018)
- Asselah T, "Direct-acting antivirals for the treatment of hepatitis C virus infection : optimizing current IFN-free treatment and future perspectives", Liver Int, 36(Suppl 1), pp.47~57 (2016)
- "Maviret summary of product characteristics: glecaprevir/pibrentasvir 100 mg/40 mg filmcoated tablets" (2020)[URL]
- "Application for inclusion of Maviret (glecaprevir/pibrentasvir) on the WHO Model List of Essential Medicines (EML)" (2019)[URL]
- Puoti M, "High SVR12 with 8-week and 12-week glecaprevir", pibrentasvir therapy : an integrated analysis of HCV genotype 1-6 patients without cirrhosis, 2018, pp.69, 293~300
- Brown RS Jr, "Glecaprevir", pibrentasvir for 8 weeks in treatment : naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis. The EXPEDITION-8 trial, 2020, pp.72, 441~449
- Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회
- Naganuma A, "Integrated analysis of 8-week glecaprevir", pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection, 2019, pp.54, 752~761
- Zeuzem S, "Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection", N Engl J Med, 378, pp.354~369 (2018)
- Asselah T, "Efficacy of glecaprevir", pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis, 2018, pp.16, 417~426
- Wei L, "Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia : two multicentre, phase 3 studies. A randomised, double-blind study(VOYAGE-1)and an open-label, single-arm study(VOYAGE-2)", Lancet Gastroenterol Hepatol, 5, pp.839~849 (2020)
- 박상훈, "Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study", Gut and Liver, 6(1), pp.98~106 (2012), 거트앤리버 소화기연관학회협의회
- 이혜원, "Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety", Gut and Liver, 12(3), pp.324~330 (2018), 거트앤리버 소화기연관학회협의회
- Younossi ZM, "Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection", J Viral Hepat, 25, pp.1429~1437 (2018)
- 조유리, "Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea", Clinical and Molecular Hepatology, 21(4), pp.358~364 (2015), 대한간학회
- Kapadia SN, "Hepatitis C management simplification from test to cure : a framework for primary care providers", Clin Ther, 40, pp.1234~1245 (2018)
- Foster GR, "Glecaprevir", pibrentasvir in patients with chronic HCV and recent drug use : an integrated analysis of 7 phase III studies, 2019, pp.194, 487~494
- 길호, "Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection", Gut and Liver, 8(1), pp.70~78 (2014), 거트앤리버 소화기연관학회협의회